查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018717

下一代癌症診斷市場：按產品、技術、癌症類型、功能、分期、應用和最終用戶分類－2026-2032年全球市場預測

Next-Generation Cancer Diagnostics Market by Product, Technology, Cancer Type, Function, Staging, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計下一代癌症診斷市場在 2025 年的價值為 150.3 億美元，在 2026 年成長至 184.7 億美元，到 2032 年達到 715.5 億美元，複合年成長率為 24.95%。

主要市場統計數據
基準年 2025 150.3億美元
預計年份：2026年 184.7億美元
預測年份：2032年 715.5億美元
複合年成長率 (%) 24.95%

整合分子診斷時代正在到來，隨著定序、多體學檢測和臨床分析的融合，癌症治療的路徑正在改變。

癌症診斷領域正從單一分析物檢測轉向整合分子檢測、高性能定序和高級分析技術的綜合性、數據豐富的平台。臨床醫生和研究機構越來越需要能夠提供貫穿整個診療週期（從風險分層和早期檢測到治療監測）的可操作性資訊的診斷方法。在技​​術小型化、檢測靈敏度提高以及生物標記與標靶治療之間轉化聯繫增強的推動下，診斷工作流程正在重組，以提供更快、更準確的結果，從而指導臨床決策。

我們確定了關鍵的技術、監管和供應鏈轉折點，這些轉折點正在加速精準癌症診斷在所有醫療保健機構中的廣泛應用。

診斷領域的變革正沿著多個相互依存的方向展開。首先，技術的成熟使得以往僅限於研究環境的檢測方法能夠應用於臨床檢查室，並擁有檢驗的工作流程和品管。其次，分析技術的進步（尤其是機器學習和雲端平台）正在將複雜的分子訊號轉化為臨床可解讀的輸出結果，降低了臨床醫生獲取清晰、可操作結果的門檻。第三，健保報銷機制和法規環境也不斷發展，以適應伴隨診斷和適應性檢測的模式，使得實證醫學成為產品開發和打入市場策略的核心要素。

本研究評估了預計在 2025 年實施的累積關稅措施對診斷領域的供應鏈、採購預算和策略製造選擇所產生的連鎖反應。

貿易和關稅政策環境是診斷公司面臨的一項重大戰略不確定性來源，尤其是在各國政府圖平衡國內產業優先事項與創新需求之際。已宣布或預計2025年實施的累積關稅措施可能會影響整個診斷價值鏈的成本，預計進口設備、專用試劑和某些半導體相關組件將受到顯著影響。這些事態發展可能會推高檢查室設備和耗材的到貨成本，對採購預算造成壓力，並延緩臨床環境中的常規升級。

我們對多方面的細分方案進行了詳細分析，該方案協調了產品分類、技術、臨床適應症和最終用戶需求，並優先考慮商業化路徑。

一套精細的細分框架揭示了各個領域（包括產品類型、技術、癌症適應症、功能應用、疾病分期和最終用戶）的機會與營運挑戰的交匯點。按產品分類，該生態系統包含“儀器”、“試劑和耗材”以及“軟體服務”，其中儀器進一步細分為“分析儀器”和“定序儀”。這種區分有助於明確資本投資模式和經常性收入趨勢。按技術分類，該細分市場涵蓋DNA微陣列、實驗室晶片和逆轉錄PCR平台、下一代定序、蛋白質微陣列以及具有多重PCR功能的qPCR，每種技術都具有獨特的靈敏度、處理能力和資訊處理要求，從而影響實驗室的工作流程。

評估美洲、歐洲、中東和非洲以及亞太地區的採用趨勢和商業化需求，並利用這些資訊制定區域擴張策略。

預計區域趨勢將持續影響下一代診斷技術的應用管道、監管方式和經營模式。美洲地區擁有強大的轉化研發體系，這得益於積極的臨床試驗和眾多能夠快速部署先進平台的標準實驗室；然而，各國家和地方政府的支付方環境和採購政策存在差異。歐洲、中東和非洲的監管體系則呈現出多元化的特點，各國在努力協調監管的同時，也各自製定了不同的報銷架構。在這些市場，策略夥伴關係和本地檢驗測試對於擴大應用至關重要。亞太地區擁有大規模的公共衛生篩檢計畫和快速發展的私部門能力，正在推動對經濟高效的檢測方法和高效能定序解決方案的需求。

對不斷變化的競爭動態的分析：平台整合、臨床夥伴關係和數據驅動的差異化將決定癌症診斷領域的贏家。

診斷生態系內的競爭動態日益呈現出平台融合、策略聯盟以及傳統供應商之間界線模糊化的特徵。成熟的儀器製造商正在整合軟體和服務，以提供端到端的解決方案；而專業的檢測開發公司則與資訊學公司合作，將複雜的輸出結果轉化為臨床決策支援。參與企業正在挑戰現有的成本結構，並帶來創新的化學技術和新型微型化方法，開啟新的臨床應用。在整個生態系統中，與學術機構和臨床機構的合作仍然是臨床檢驗的關鍵機制，能夠加快核准流程，並建立更強大的證據體系，從而推動技術的應用。

在診斷領域，領導企業正在實施實際有效的策略措施，以加速技術應用、降低供應鏈風險並建立永續的經營模式。

產業領導者應推動一系列合作舉措，使技術能力與實際市場狀況相適應。首先，投資於模組化、互通性的平台，實現分階段的功能升級，而無需對檢查室設備進行全面改造。這有助於降低採用門檻，並維持客戶的終身價值。其次，透過認證多家關鍵試劑和組件供應商，並探索區域製造合作夥伴關係，實現採購策略多元化，進而降低關稅和籌資策略風險。第三，將真實世界資料（REW）收集納入產品藍圖，並設計上市後監測和註冊機制，以證明產品的臨床效用和對支付者的價值。

本節說明了一種多層次的混合方法研究方法，該方法結合了第一手訪談、第二手資訊和透明檢驗，以支持策略見解。

本調查方法結合了定性和定量方法，以確保研究結果的穩健性和可重複性。主要調查包括對檢查室管理人員、臨床腫瘤學家、採購經理和技術開發人員進行詳細訪談，以了解決策因素、檢驗要求和營運限制。次要調查整合了同行評審文獻、監管指導文件和公開的臨床實驗室註冊信息，以闡明技術主張並識別證據缺口。採用資料檢驗法，將訪談結果與已發表的研究和公開的監管文件進行交叉比對。

為了指導癌症診斷中的策略決策，我們需要整合技術、商業性和營運要求，以得出結論。

總之，下一代癌症診斷正處於一個轉折點，技術成熟度、數據分析和不斷變化的醫療保健重點在此交匯，創造了新的臨床和商業性機會。從單一檢測向整合平台的轉變預計將受到監管政策的明確、支付方的參與以及檢查室營運實踐的推動。供應鏈挑戰和不斷變化的定價結構增加了複雜性，但也獎勵製造商在產品設計、區域生產和服務交付方面進行創新。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 下一代癌症診斷市場：依產品分類

  • 裝置
    • 分析器
    • 序列器
  • 試劑和耗材
  • 軟體服務

第9章：下一代癌症診斷市場：依技術分類

  • DNA微陣列
  • 點陣實驗室和逆轉錄PCR
  • 下一代定序
  • 蛋白質微陣列
  • qPCR和多重PCR

第10章 下一代癌症診斷市場：依癌症類型分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第11章 下一代癌症診斷市場：按功能分類

  • 生物標記開發
  • CTC分析
  • 表觀遺傳分析
  • 基因分析
  • 蛋白質體學分析

第12章 下一代癌症診斷市場：依疾病階段分類

  • 早期的
  • 晚期

第13章 下一代癌症診斷市場：按應用分類

  • 癌症篩檢
  • 伴隨診斷
  • 預後診斷
  • 風險評估
  • 治療監測

第14章 下一代癌症診斷市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院
  • 研究機構
    • 學術機構
    • 政府機構

第15章 下一代癌症診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 下一代癌症診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 下一代癌症診斷市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國下一代癌症診斷市場

第19章：中國下一代癌症診斷市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive BIoTechnologies Corporation
  • Agena Bioscience, Inc.（Mesa Laboratories, Inc.）
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Almac Group
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • Biological Dynamics Inc.
  • bioMerieux SA
  • BioNTech SE
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • NeoGenomics Laboratories
  • Novartis AG
  • OPKO Health, Inc.
  • Oxford Nanopore Technologies Limited
  • Perkin Elmer, Inc.
  • Qiagen NV
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Telerad Tech
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-AD36CD898567

The Next-Generation Cancer Diagnostics Market was valued at USD 15.03 billion in 2025 and is projected to grow to USD 18.47 billion in 2026, with a CAGR of 24.95%, reaching USD 71.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.03 billion
Estimated Year [2026] USD 18.47 billion
Forecast Year [2032] USD 71.55 billion
CAGR (%) 24.95%

Framing the era of integrated molecular diagnostics where sequencing, multi-omic assays, and clinical analytics converge to transform cancer care pathways

The landscape of cancer diagnostics is shifting from single-analyte tests toward integrated, data-rich platforms that combine molecular assays, high-throughput sequencing, and advanced analytics. Increasingly, clinicians and research centers demand diagnostics that provide actionable insights across the continuum of care-from risk stratification and early detection to therapeutic monitoring. Driven by technological miniaturization, improvements in assay sensitivity, and stronger translational links between biomarkers and targeted therapies, diagnostic workflows are being reimagined to deliver faster, more precise answers that can guide clinical decision-making.

This introduction frames the broader thematic forces reshaping the industry: convergence of wet-lab innovation with computational biology, heightened expectations for interoperability and real-world evidence, and rising pressure to reduce time-to-result without sacrificing analytical rigor. As adoption expands beyond specialized centers into community hospitals and reference laboratories, stakeholders face complex choices regarding platform selection, integration of multi-omic data, and investment in workforce capabilities. The content that follows synthesizes these dynamics, highlights emergent inflection points, and outlines practical implications for executives and technical leaders who must align strategy with the accelerating pace of innovation.

Identifying the pivotal technological, regulatory, and supply chain inflection points that are accelerating adoption of precision cancer diagnostics across care settings

Transformative shifts in the diagnostics landscape are unfolding along multiple, interdependent axes. First, technological maturation is enabling assays that were once confined to research settings to be deployed in clinical laboratories with validated workflows and quality controls. Second, analytic advances-particularly in machine learning and cloud-based platforms-are converting complex molecular signals into clinically interpretable outputs, thereby lowering the barrier to adoption for clinicians who require clear, actionable results. Third, reimbursement and regulatory ecosystems are evolving to accommodate companion diagnostics and adaptive testing paradigms, making evidence generation a central component of product development and market access strategies.

Concurrently, strategic sourcing and manufacturing approaches are being redesigned to mitigate supply chain vulnerabilities exposed by recent global disruptions. Stakeholders are shifting toward modular systems and reagent standardization to reduce operational complexity while preserving assay performance. Alliances between diagnostic developers, academic centers, and healthcare providers are becoming more common, reflecting a collaborative model of innovation where co-development and data sharing accelerate clinical validation. Taken together, these shifts are creating an environment in which speed, precision, and interoperability determine which technologies transition from promising prototypes to clinical staples.

Assessing how cumulative tariff measures projected in 2025 could reverberate through supply chains, procurement budgets, and strategic manufacturing choices in diagnostics

The policy landscape for trade and tariffs adds an important layer of strategic uncertainty for diagnostic companies, particularly as governments seek to balance domestic industrial priorities with innovation imperatives. Cumulative tariff measures announced or anticipated in 2025 are likely to affect costs across the diagnostic value chain, with pronounced effects on imported instruments, specialty reagents, and certain semiconductor-dependent components. These dynamics can increase the landed cost of equipment and consumables for laboratories, creating pressure on procurement budgets and potentially delaying routine upgrades in clinical settings.

In response, organizations are evaluating near-term tactics and medium-term structural changes. Near-term tactics include renegotiating supplier contracts, increasing buffer inventories for critical reagents, and optimizing assay workflows to reduce per-test reagent consumption. Over the medium term, manufacturers and service providers may accelerate regional manufacturing investments, qualify additional contract manufacturers, and redesign product architectures to minimize exposure to tariff-sensitive parts. Importantly, these adjustments are not deterministic; regulatory approvals, quality assurance processes, and capital constraints will shape the pace at which supply chains can be reconfigured. From a clinical perspective, laboratories should anticipate incremental price pressures but can mitigate downstream impact through operational efficiencies and selective prioritization of high-value assays that demonstrably improve patient outcomes.

Delving into a multifaceted segmentation schema that aligns product classes, technologies, clinical indications, and end-user needs to prioritize commercialization pathways

A nuanced segmentation framework reveals where opportunities and operational challenges converge across product types, technologies, cancer indications, functional applications, staging, and end-users. Based on product, the ecosystem encompasses Instruments, Reagents & Consumables, and Software & Services, with Instruments further differentiated into Analyzers and Sequencers; this distinction clarifies capital investment patterns and recurring revenue dynamics. Based on technology, the landscape spans DNA Microarrays, Lab-on-a-chip and Reverse Transcriptase-PCR platforms, Next-generation Sequencing, Protein Microarrays, and qPCR with Multiplexing capabilities, each bringing distinct sensitivity, throughput, and informatics requirements that shape laboratory workflows.

Based on cancer type, diagnostics are focused across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer, where differing biomarker architectures and screening paradigms dictate test design and clinical utility studies. Based on function, capabilities range across Biomarker Development, Circulating Tumor Cell analysis, Epigenetic profiling, Genetic analysis, and Proteomic interrogation, which together form integrated pipelines that can enable companion diagnostics and therapeutic monitoring. Based on staging, differentiation between Early Detection and Progressive Staging highlights the divergent performance thresholds and population-level implications of screening versus disease monitoring. Finally, based on application, diagnostic use cases include Cancer Screening, Companion Diagnostics, Prognostics, Risk Assessment, and Therapeutic Monitoring, and end-user settings encompass Diagnostic Laboratories, Hospitals, and Research Institutes-with Research Institutes further categorized into Academic and Governmental entities-each of which demands tailored service models, validation pathways, and commercialization approaches. Synthesizing these segmentation dimensions provides a roadmap for prioritizing product development, clinical validation investments, and go-to-market tactics that align with specific clinical and operational value propositions.

Evaluating regional adoption patterns and commercialization imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform geographic expansion strategies

Regional dynamics will continue to shape adoption trajectories, regulatory approaches, and commercial models for next-generation diagnostics. The Americas demonstrate a strong translational pipeline with significant clinical trial activity and a concentration of reference laboratories that can rapidly adopt advanced platforms, though regional payer landscapes and procurement policies vary across national and subnational boundaries. Europe, Middle East & Africa present a heterogeneous regulatory mosaic where harmonization efforts coexist with country-specific reimbursement frameworks; in these markets, strategic partnerships and local validation studies are often essential to scale adoption. Asia-Pacific features a combination of high-volume public health screening initiatives and rapidly expanding private-sector capabilities, driving demand for both cost-effective assays and high-throughput sequencing solutions.

Across these regions, common themes emerge: the need for robust local evidence generation, the value of interoperability with electronic health records, and the importance of tailored service models that account for laboratory infrastructure and workforce competencies. Companies pursuing geographic expansion should layer regulatory strategy with supply chain resilience and demonstrate clinical utility in region-specific cohorts to accelerate acceptance. Moreover, cross-border collaborations for data sharing and multicenter validation can reduce duplication of effort and speed the translation of promising assays into routine clinical use.

Analyzing evolving competitive dynamics where platform integration, clinical partnerships, and data-driven differentiation define winners in cancer diagnostics

Competitive dynamics in the diagnostics ecosystem are increasingly characterized by platform convergence, strategic collaborations, and a blurring of traditional vendor boundaries. Established instrument manufacturers are integrating software and services to offer end-to-end solutions, while specialized assay developers are partnering with informatics companies to translate complex outputs into clinical decision support. Emerging entrants bring disruptive chemistry or novel miniaturization approaches that challenge incumbent cost structures and open new clinical applications. Across the ecosystem, alliances with academic and clinical institutions remain a key mechanism for clinical validation, enabling faster pathway development and stronger evidence packages to support adoption.

Strategic differentiation is often achieved through a combination of proprietary reagent portfolios, validated workflow integrations, and robust customer support that minimizes laboratory disruption during technology transitions. Companies that invest in scalable cloud architectures, strong data governance, and explainable analytics gain advantage by enabling payers and providers to quantify clinical impact. At the same time, a pragmatic focus on interoperability standards and regulatory readiness reduces friction during market entry. For corporate strategists, balancing short-term commercial wins with long-term investments in platform extensibility and clinical partnerships will determine which organizations lead the next phase of diagnostic innovation.

Practical, high-impact strategic moves for leaders to accelerate adoption, de-risk supply chains, and build durable commercial models in diagnostics

Industry leaders should pursue a coordinated set of actions that align technological capability with pragmatic market realities. First, invest in modular, interoperable platforms that allow incremental capability upgrades without requiring wholesale laboratory retooling; this lowers adoption barriers and preserves customer lifetime value. Second, diversify sourcing strategies by qualifying multiple suppliers for critical reagents and subassemblies and by exploring regional manufacturing alliances to mitigate tariff and logistics risks. Third, embed real-world evidence generation into product roadmaps, designing post-market studies and registries that demonstrate clinical utility and value to payers.

In parallel, prioritize partnerships with healthcare systems and academic centers to co-develop clinical workflows and reimbursement dossiers, and invest in clinician education to accelerate appropriate test utilization. From an operational perspective, adopt lean validation processes and automation to reduce turnaround times while maintaining analytical rigor. Finally, ensure that commercial models are flexible-offering a mix of capital purchase, reagent-as-a-service, and subscription-based software licensing-to match the diverse procurement preferences of hospitals, reference laboratories, and research institutes. These recommendations, taken together, will enhance resilience, accelerate adoption, and maximize clinical impact.

Explaining the layered mixed-methods research approach that combines primary interviews, secondary sources, and transparent validation to underpin strategic insights

The research methodology combines qualitative and quantitative approaches to ensure robust, reproducible insights. Primary research included in-depth interviews with laboratory directors, clinical oncologists, procurement leaders, and technical developers to capture decision drivers, validation requirements, and operational constraints. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, and public clinical trial registries to contextualize technological claims and identify evidence gaps. Data triangulation was employed to cross-validate interview findings with published studies and publicly available regulatory filings.

Analytical processes included thematic coding of qualitative inputs, validation workshops with subject-matter experts, and scenario analysis to assess how policy or supply chain shocks could influence strategic choices. Where applicable, methodological transparency was maintained through documentation of interview protocols, inclusion criteria for literature reviews, and assumptions used in scenario modelling. This layered approach ensures that conclusions are grounded in practitioner experience and corroborated by objective sources, providing a defensible basis for strategic decision-making while acknowledging limitations inherent to evolving technological and policy environments.

Concluding synthesis that integrates technological, commercial, and operational imperatives to guide strategic decision-making in cancer diagnostics

In summary, next-generation cancer diagnostics are at an inflection point where technological maturity, data analytics, and shifting healthcare priorities converge to create novel clinical and commercial opportunities. The transition from isolated assays to integrated platforms will be mediated by regulatory clarity, payer engagement, and the practicalities of laboratory operations. Supply chain stressors and evolving tariff landscapes introduce complexity, but they also create incentives for manufacturers to innovate in product design, regional manufacturing, and service delivery.

For stakeholders across the ecosystem, success will hinge on aligning product development with demonstrable clinical value, investing in interoperable and scalable systems, and forging partnerships that accelerate evidence generation and implementation. By synthesizing segmentation insights, regional dynamics, and competitive trends, this report equips executives with a coherent framework for prioritizing investments and operational changes that translate scientific promise into improved patient outcomes. The path forward is both challenging and navigable, provided organizations adopt disciplined, evidence-centered strategies that anticipate change and adapt rapidly.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Cancer Diagnostics Market, by Product

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Sequencers
  • 8.2. Reagents & Consumables
  • 8.3. Software & Services

9. Next-Generation Cancer Diagnostics Market, by Technology

  • 9.1. DNA Microarrays
  • 9.2. Lab-on- a- chip & Reverse Transcriptase-PCR
  • 9.3. Next-generation Sequencing
  • 9.4. Protein Microarrays
  • 9.5. qPCR & Multiplexing

10. Next-Generation Cancer Diagnostics Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. Next-Generation Cancer Diagnostics Market, by Function

  • 11.1. Biomarker Development
  • 11.2. CTC Analysis
  • 11.3. Epigenetic Analysis
  • 11.4. Genetic Analysis
  • 11.5. Proteomic Analysis

12. Next-Generation Cancer Diagnostics Market, by Staging

  • 12.1. Early Detection
  • 12.2. Progressive Staging

13. Next-Generation Cancer Diagnostics Market, by Application

  • 13.1. Cancer Screening
  • 13.2. Companion Diagnostics
  • 13.3. Prognostics
  • 13.4. Risk Assessment
  • 13.5. Therapeutic Monitoring

14. Next-Generation Cancer Diagnostics Market, by End-User

  • 14.1. Diagnostic Laboratories
  • 14.2. Hospitals
  • 14.3. Research Institutes
    • 14.3.1. Academic
    • 14.3.2. Governmental

15. Next-Generation Cancer Diagnostics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Next-Generation Cancer Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Next-Generation Cancer Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Next-Generation Cancer Diagnostics Market

19. China Next-Generation Cancer Diagnostics Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Adaptive Biotechnologies Corporation
  • 20.7. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • 20.8. Agilent Technologies, Inc.
  • 20.9. Akadeum Life Sciences
  • 20.10. Almac Group
  • 20.11. Becton, Dickinson & Company
  • 20.12. Bio-Techne Corporation
  • 20.13. Biological Dynamics Inc.
  • 20.14. bioMerieux SA
  • 20.15. BioNTech SE
  • 20.16. Castle Biosciences Inc.
  • 20.17. Danaher Corporation
  • 20.18. Exact Sciences Corporation
  • 20.19. F. Hoffmann-La Roche Ltd.
  • 20.20. GE HealthCare
  • 20.21. Hologic Inc.
  • 20.22. Illumina, Inc.
  • 20.23. Johnson & Johnson Services, Inc.
  • 20.24. Konica Minolta, Inc.
  • 20.25. Koninklijke Philips N.V.
  • 20.26. NeoGenomics Laboratories
  • 20.27. Novartis AG
  • 20.28. OPKO Health, Inc.
  • 20.29. Oxford Nanopore Technologies Limited
  • 20.30. Perkin Elmer, Inc.
  • 20.31. Qiagen N.V.
  • 20.32. Siemens Healthineers AG
  • 20.33. Sysmex Corporation
  • 20.34. Telerad Tech
  • 20.35. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGRESSIVE STAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GOVERNMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 196. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 203. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 226. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 233. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 235. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 236. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 238. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 243. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 245. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STAGING, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)